Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Income from Continuing Operations (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Income from Continuing Operations for 13 consecutive years, with 46347000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 0.55% to 46347000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 183124000.0 through Dec 2025, up 15.45% year-over-year, with the annual reading at 183124000.0 for FY2025, 14.98% up from the prior year.
  • Income from Continuing Operations hit 46347000.0 in Q4 2025 for Coherus Oncology, down from 44517000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 29900000.0 in Q2 2021 to a low of 172947000.0 in Q1 2021.
  • Historically, Income from Continuing Operations has averaged 60819950.0 across 5 years, with a median of 47498500.0 in 2024.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 700.7% in 2021 and later surged 54.25% in 2023.
  • Year by year, Income from Continuing Operations stood at 45683000.0 in 2021, then decreased by 28.85% to 58862000.0 in 2022, then plummeted by 35.32% to 79653000.0 in 2023, then surged by 42.13% to 46093000.0 in 2024, then fell by 0.55% to 46347000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for CHRS at 46347000.0 in Q4 2025, 44517000.0 in Q3 2025, and 44862000.0 in Q2 2025.